Cost-Effectiveness of Ivabradine for Heart Failure in the United States.
Ontology highlight
ABSTRACT: Ivabradine is a heart rate-lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost-effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage payer. A cost-effectiveness, cohort-based Markov model using a state transition approach tracked a cohort of heart failure patients with heart rate ≥70 beats per minute in sinus rhythm who were treated with ivabradine+background therapy or background therapy alone. Model inputs, including adjusted hazard ratios, rates of hospitalization and mortality, adverse events, and utility-regression equations, were derived from a large US claims database and SHIFT (Systolic Heart failure treatment with the If inhibitor i
SUBMITTER: Kansal AR
PROVIDER: S-EPMC4889192 | biostudies-literature | 2016 May
REPOSITORIES: biostudies-literature
ACCESS DATA